Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda

William I. Towler, Linda Barlow-Mosha, Jessica D. Church, Danstan S Bagenda, Patrick Ajuna, Micheal Mubiru, Philippa Musoke, Susan H. Eshleman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We analyzed drug resistance in HIV-infected Ugandan children who received antiretroviral therapy in a prospective, observational study (2004-2006); some children had prior single-dose nevirapine (sdNVP) exposure. Children received stavudine (d4T), lamivudine (3TC), and nevirapine (NVP); treatment was continued if they were clinically and immunologically stable. Samples with >1,000 copies/ml HIV RNA were analyzed by using the ViroSeq HIV Genotyping System (ViroSeq). Subtype A and D pretreatment samples also were analyzed with the LigAmp assay (for K103N, Y181C, and G190A). ViroSeq results were obtained for 74 pretreatment samples (35 from sdNVP-exposed children (median age, 19 months) and 39 from sdNVP-unexposed children (median age, 84 months). This included 39 subtype A, 22 subtype D, 1 subtype C, and 12 inter-subtype recombinant samples. One sample had nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one had nucleoside reverse transcriptase inhibitor (NRTI) resistance, and three had protease inhibitor (PI) resistance. Y181C was detected by using LigAmp in five pretreatment samples [four (14.8%) of 37 samples from sdNVP-exposed children, one (4.2%) of 24 samples from children without prior sdNVP exposure; p=0.35]. Among children who were not virally suppressed at 48 weeks of treatment, all 12 tested had NNRTI resistance, as well as resistance to 3TC and emtricitibine (FTC); three had resistance to other NRTIs. Seven of those children had a ViroSeq result at 96 weeks of treatment; four of the seven acquired resistance to additional NRTIs by 96 weeks. In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance.

Original languageEnglish (US)
Pages (from-to)563-568
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume26
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Uganda
Drug Resistance
HIV Infections
HIV-1
Nevirapine
Reverse Transcriptase Inhibitors
Lamivudine
Therapeutics
HIV
Stavudine
Protease Inhibitors
Nucleosides
Observational Studies
Prospective Studies
RNA

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Towler, W. I., Barlow-Mosha, L., Church, J. D., Bagenda, D. S., Ajuna, P., Mubiru, M., ... Eshleman, S. H. (2010). Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Research and Human Retroviruses, 26(5), 563-568. https://doi.org/10.1089/aid.2009.0164

Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. / Towler, William I.; Barlow-Mosha, Linda; Church, Jessica D.; Bagenda, Danstan S; Ajuna, Patrick; Mubiru, Micheal; Musoke, Philippa; Eshleman, Susan H.

In: AIDS Research and Human Retroviruses, Vol. 26, No. 5, 01.05.2010, p. 563-568.

Research output: Contribution to journalArticle

Towler, WI, Barlow-Mosha, L, Church, JD, Bagenda, DS, Ajuna, P, Mubiru, M, Musoke, P & Eshleman, SH 2010, 'Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda', AIDS Research and Human Retroviruses, vol. 26, no. 5, pp. 563-568. https://doi.org/10.1089/aid.2009.0164
Towler, William I. ; Barlow-Mosha, Linda ; Church, Jessica D. ; Bagenda, Danstan S ; Ajuna, Patrick ; Mubiru, Micheal ; Musoke, Philippa ; Eshleman, Susan H. / Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. In: AIDS Research and Human Retroviruses. 2010 ; Vol. 26, No. 5. pp. 563-568.
@article{3b8e2f8465a64ac4b8be6b17ba2b626b,
title = "Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda",
abstract = "We analyzed drug resistance in HIV-infected Ugandan children who received antiretroviral therapy in a prospective, observational study (2004-2006); some children had prior single-dose nevirapine (sdNVP) exposure. Children received stavudine (d4T), lamivudine (3TC), and nevirapine (NVP); treatment was continued if they were clinically and immunologically stable. Samples with >1,000 copies/ml HIV RNA were analyzed by using the ViroSeq HIV Genotyping System (ViroSeq). Subtype A and D pretreatment samples also were analyzed with the LigAmp assay (for K103N, Y181C, and G190A). ViroSeq results were obtained for 74 pretreatment samples (35 from sdNVP-exposed children (median age, 19 months) and 39 from sdNVP-unexposed children (median age, 84 months). This included 39 subtype A, 22 subtype D, 1 subtype C, and 12 inter-subtype recombinant samples. One sample had nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one had nucleoside reverse transcriptase inhibitor (NRTI) resistance, and three had protease inhibitor (PI) resistance. Y181C was detected by using LigAmp in five pretreatment samples [four (14.8{\%}) of 37 samples from sdNVP-exposed children, one (4.2{\%}) of 24 samples from children without prior sdNVP exposure; p=0.35]. Among children who were not virally suppressed at 48 weeks of treatment, all 12 tested had NNRTI resistance, as well as resistance to 3TC and emtricitibine (FTC); three had resistance to other NRTIs. Seven of those children had a ViroSeq result at 96 weeks of treatment; four of the seven acquired resistance to additional NRTIs by 96 weeks. In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance.",
author = "Towler, {William I.} and Linda Barlow-Mosha and Church, {Jessica D.} and Bagenda, {Danstan S} and Patrick Ajuna and Micheal Mubiru and Philippa Musoke and Eshleman, {Susan H.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1089/aid.2009.0164",
language = "English (US)",
volume = "26",
pages = "563--568",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda

AU - Towler, William I.

AU - Barlow-Mosha, Linda

AU - Church, Jessica D.

AU - Bagenda, Danstan S

AU - Ajuna, Patrick

AU - Mubiru, Micheal

AU - Musoke, Philippa

AU - Eshleman, Susan H.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - We analyzed drug resistance in HIV-infected Ugandan children who received antiretroviral therapy in a prospective, observational study (2004-2006); some children had prior single-dose nevirapine (sdNVP) exposure. Children received stavudine (d4T), lamivudine (3TC), and nevirapine (NVP); treatment was continued if they were clinically and immunologically stable. Samples with >1,000 copies/ml HIV RNA were analyzed by using the ViroSeq HIV Genotyping System (ViroSeq). Subtype A and D pretreatment samples also were analyzed with the LigAmp assay (for K103N, Y181C, and G190A). ViroSeq results were obtained for 74 pretreatment samples (35 from sdNVP-exposed children (median age, 19 months) and 39 from sdNVP-unexposed children (median age, 84 months). This included 39 subtype A, 22 subtype D, 1 subtype C, and 12 inter-subtype recombinant samples. One sample had nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one had nucleoside reverse transcriptase inhibitor (NRTI) resistance, and three had protease inhibitor (PI) resistance. Y181C was detected by using LigAmp in five pretreatment samples [four (14.8%) of 37 samples from sdNVP-exposed children, one (4.2%) of 24 samples from children without prior sdNVP exposure; p=0.35]. Among children who were not virally suppressed at 48 weeks of treatment, all 12 tested had NNRTI resistance, as well as resistance to 3TC and emtricitibine (FTC); three had resistance to other NRTIs. Seven of those children had a ViroSeq result at 96 weeks of treatment; four of the seven acquired resistance to additional NRTIs by 96 weeks. In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance.

AB - We analyzed drug resistance in HIV-infected Ugandan children who received antiretroviral therapy in a prospective, observational study (2004-2006); some children had prior single-dose nevirapine (sdNVP) exposure. Children received stavudine (d4T), lamivudine (3TC), and nevirapine (NVP); treatment was continued if they were clinically and immunologically stable. Samples with >1,000 copies/ml HIV RNA were analyzed by using the ViroSeq HIV Genotyping System (ViroSeq). Subtype A and D pretreatment samples also were analyzed with the LigAmp assay (for K103N, Y181C, and G190A). ViroSeq results were obtained for 74 pretreatment samples (35 from sdNVP-exposed children (median age, 19 months) and 39 from sdNVP-unexposed children (median age, 84 months). This included 39 subtype A, 22 subtype D, 1 subtype C, and 12 inter-subtype recombinant samples. One sample had nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, one had nucleoside reverse transcriptase inhibitor (NRTI) resistance, and three had protease inhibitor (PI) resistance. Y181C was detected by using LigAmp in five pretreatment samples [four (14.8%) of 37 samples from sdNVP-exposed children, one (4.2%) of 24 samples from children without prior sdNVP exposure; p=0.35]. Among children who were not virally suppressed at 48 weeks of treatment, all 12 tested had NNRTI resistance, as well as resistance to 3TC and emtricitibine (FTC); three had resistance to other NRTIs. Seven of those children had a ViroSeq result at 96 weeks of treatment; four of the seven acquired resistance to additional NRTIs by 96 weeks. In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=77952556299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952556299&partnerID=8YFLogxK

U2 - 10.1089/aid.2009.0164

DO - 10.1089/aid.2009.0164

M3 - Article

VL - 26

SP - 563

EP - 568

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -